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1.1 Host Restriction factors 
 
The innate and acquired immune system represent an effective defence against virus infection, but this 
response is triggered only by recognition of an already replicating virus (Bieniasz P. et al. 2004 Nat 
Immunol). In addition to the conventional immune response many mammals, including humans, have 
evolved a complex of cellular proteins, named host restriction factors, that function as inhibitors of 
retroviral replication. These cellular factors are constitutively expressed or enhanced by interferons 
(Neil S, Bieniasz P. et al. 2009 J Interferon Cytokine Res) and represent an important part of intrinsic 
immunity against viral infection (Bieniasz P. et al. 2004 Nat Immunol). Nevertheless, retroviruses have 
evolved mechanisms to inactivate or overcome the block of infection through viral proteins that can 
efficiently counteract the inhibitory effect of some cellular restriction factors (Strebel K. et al. 2009 
BMC Med; Goff SP. 2004 Mol Cell; Rowland-Jones S. et al. 2001 Cell). At present, the knowledge of 
the mechanisms by which restriction factors interfere with retroviral replication, and how their effects 
are avoided by virus, is sufficiently clear in particular for HIV-1. To date, three major types of 
antiretroviral restriction factor that are potentially capable of inhibiting HIV-1 replication have been 
identified (Sheehy AM. et al. 2002 Nature; Stremlau M. et al. 2004 Nature; Neil SJ. et al. 2008 
Nature): APOBEC3G, TRIM5α and tetherin (Scheme 1). Other cellular proteins were shown to 
interfere with viral infection (Ozato K. et al. 2008 Nat Rev Immunol). Here we focused our attention on 
two cellular factors, namely CIITA, well-studied in our laboratory, and TRIM22, that was shown to 
have antiviral activity by suppressing HIV-1 transcription (Ozato K.et al.2008 Nat Rev Immunol). Of 
particular interest, in our laboratory we have demonstrated that the cellular factor CIITA, the master 
regulator of MHC Class II gene transcription, affected HIV-1 replication by inhibiting the viral 
transactivator Tat (Accolla R. et al. 2002 Eur J Immunol.). In addition, we have recently described 
CIITA as a potent inhibitor of HTLV-1 and HTLV-2 replication, affecting their respective viral 
transactivators Tax. These findings suggest that CIITA acts as a viral restriction factor for human 






Scheme 1. The most important host restriction factors capable of inhibiting HIV-1 replication, and their 
viral antagonists evolved by the virus to avoid these host defenses. TRIM5 recognizes incoming HIV-1 
capsids and inactivates them; Cyclophilin A also binds to incoming capsids and can affect recognition 
by TRIM5. APOBEC3 proteins can be incorporated into assembling HIV-1 particles, and catalyze the 
deamination of nascent minus strand DNA during the subsequent round of infection. The HIV-1 Vif 
protein binds to APOBEC3 proteins, and also to a Cullin5-based ubiquitin ligase complex. This results 
in APOBEC3 protein ubiquitination and degradation in proteasomes. Tetherin is a cell surface protein 
that causes entrapment of nascent virions on the infected cell surface. Vpu antagonizes tetherin by 
sequestering tetherin from virions and by reducing the levels of tetherin on the cell surface. (Neil S, 
Bieniasz P. 2009 J Interferon Cytokine Res) 
 
APOBEC3 family 
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) family of cytidine 
deaminases represents the first group of proteins identified as inhibitor of HIV-1 replication (Sheehy 
AM. et al. 2002 Nature). Among them, APOBEC3G is the most studied in the context of HIV-1 
(Bishop KN. et al. 2004 Science; Zennou V. et al. 2006 Virology; Virgen CA. et al. 2007 J Virol). 
Specifically, it can be incorporated into retroviral particles, by binding the packaged RNA (Svarovskaia 
ES. et al. 2004 J Biol Chem; Zennou V. et al. 2004 J Virol; Wang FZ. et al. 2007 Human 
Herpesviruses), and carried by the virion to a new target cell. During reverse transcription APOBEC3G 
deaminates the deoxycytidines of the viral minus-strand DNA, generating minus strand DNA 
containing many deoxyuracil nucleotides, whose replication results in G to A hypermutations in the 
complementary plus DNA strand (Chen D. et al. 2003 Cell.; Lecossier D. et al. 2003 Science). 
However, recent finding suggest that the induced-mutation capacity of APOBEC3 seems to constitute 
only a part of the mechanism by which antiviral activity is achieved (Newman EN. et al. 2005 Curr 
Biol) 
HIVΔ1 Vif protein counteracts APOBEC3G by blocking its incorporation into the viral particles. Vif 
binds to APOBEC3G and to the Cul5–elongin B–elongin C–Rbx1 ubiquitin ligase complex, causing 
APOBEC3G polyubiquitination and subsequent degradation by proteasoma (Mariani R. et al. 2003 
Cell). Of particular interest for this work is APOBEC3A, whose deaminase activity is induced by IFN 
in monocytes and macrophages  (Thielen, B. K. et al. 2010 J Biol). In this regard, recent reports 
suggested that endogenously produced IFN- contributes to restricted HIV-1 viral replication in U937 
promonocytic cells (Mace.K. et al. 1989 Virology). 
Theterin  
Tetherin (also known as BST-2, CD317, or HM1.24) is an inhibitor of HIV-1 particles release from the 
infected cells (Neil SJ. et al. 2008 Nature., 2008; Van Damme N. et al. 2008 Cell Host Microbe). It is a 
membrane protein, with unusual topology, which is essential for its antiviral function (Kupzig S. et al. 
2003 Traffic). Tetherin seems to induce the formation of protein-based tethers that cause the retention 
of HIV-1 particles on infected cell surfaces (Neil SJ. et al. 2006 PLoS Pathog; Neil SJ. et al. 2008 
Nature), preventing their spreading to the uninfected cells. Subsequently, tetherin-retained virions can 
be re-internalized into the infected cell and targeted to late endosomes, where they may be retained or 
destroyed by lysosomal enzymes (Neil SJ. et al. 2006 PLoS Pathog). Tetherin expression is induced by 
type I interferon, (Blasius AL. et al. 2006 J Immunol). In absence of stimulation tetherin was found 
only in a certain subtype of cells, suggesting that it is part of a specific innate immune defense, that 
limits the replication of many enveloped viruses (Neil SJ. et al. 2007 Cell Host Microbe; Neil SJ. et al. 
2008 Nature; Jouvenet N. et al. 2009 J Virol; Kaletsky RL. et al. 2009 Proc Natl Acad Sci U S A; 
Sakuma R. et al.2009 J Biol Chem). In the case of HIV-1, the viral protein Vpu sequesters tetherin from 
sites of HIV-1 particle assembly, thereby preventing it for encountering nascent virions (Neil SJ. et al. 
2008 Nature; Jouvenet N. et al. 2009 J Virol). It has been suggested that Vpu may reduce the level of 
tetherin at the cell surface and trigger its proteasome-dependent degradation (Jouvenet N. et al. 2009 J 
Virol) 
TRIM family 
The superfamily of tripartite motif-containing (TRIM) proteins is involved in gene regulation, 
ubiquitination, DNA recombination and DNA repair (Joazeiro CA. et al. 2000 Cell; Reymond A. et al. 
2001 EMBO J ; Tissot C. et al.1995 J Biol Chem; Tissot C. et al. 1996 Genomics). Moreover, mutations 
in several TRIM proteins have been linked to human diseases. There are approximately 70 TRIM 
family members, and they are characterized by the presence of a tripartite motif, which consists of a 
RING domain, one or two B-box motifs, and a coiled-coil region (Singh R. et al. 2011 J Virol) 
(Scheme 2).  
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Scheme 2. Schematic representation of TRIM protein family 
 TRIMs share a common domain organization, with an N-terminal RING domain, followed by a B-box 
2 domain, a coiled-coil motif, and a C-terminal domain.  Some TRIMs contain a B-box 1 domain 
located between the RING and B-box 2 regions. 
 
The C-terminal region can contain any of 10 distinct motifs alone or in combination, which results in 
the designation of 9 families, C-I to C-IX36  (Ozato K. et al. 2008 Nat Rev Immunol). Structural 
analyses of these domains in several family members have greatly increased the understanding of the 
contribution of each domain to TRIM protein functions. The RING domain is a specialized zinc finger 
of 40–60 residues that bind two zinc atoms, located in the N-terminal region of almost all TRIM 
proteins, which can mediate the covalent association of proteins with ubiquitin. Studies have 
demonstrated that a lot of RING finger proteins could simultaneously bind ubiquitylation enzymes and 
the substrates through their RING finger domains and hence act as ligases in the ubiquitylation 
reaction. This function can contribute to the biological flexibility of TRIM proteins (Ozato K. et al. 
2008 Nat Rev Immunol). For example, TRIM21 functions as an E3 ligase for IRF-8 (Interferon 
Interferon regulatory factor 8) 8 (IRF-8) and contributes to the elicitation of innate immunity in 
macrophages. TRIM25 induces the Lysine 63-linked ubiquitylation of RIG-I (Retinoic Retinoic acid 
inducible gene I), I (RIG-I), which is crucial for the RIG-I signalling signaling pathway to elicit host 
antiviral innate immunity (Duan Z .et al. 2008 Biochem Biophys Res Commun). 
The RING-finger domain of several TRIM proteins, including TRIM5α and TRIM22 contains a 
specialized zinc finger (Barr SD. et al. 2008 PLoS Pathog), which has been shown to possess an E3 
ubiquitin ligase activity that triggers a cascade of ubiquitin transfer reactions to specific proteins 
leading to the tight control of the concentration or the subcellular localization of the target proteins 
(Gack MU. Et al 2007 Nature; Kallijarvi J. et al. 2005 Exp Cell Res; Kong HJ.et al. 2007 J Immunol; 
Kudryashova E. et al. 2005 J Mol Biol) (Eldin P. et al. 2009 J Gen Virol). The E3 ubiquitin ligase 
activity of the RING domain is important for the anti-retroviral function of many TRIM proteins. In the 
case of TRIM22 the conserved cys-15 and cys-18  of its RING domain are especially important for its 
biological functions (Yu S. et al.2011 Biophys Res Commun). Structural studies of several human 
TRIM B-box 1 and B-box 2 domains have shown they have ternary structures similar to those of RING 
domains, which suggests that all three domains have evolved from a common ancestral domain (Liu J. 
et al.2010 PLoS One). Indeed the B-box are zinc-binding motifs, and B-box 1 and B-box 2 are 
characterized by different consensus sequences between members of the TRIM family (Liu J. et al. 
2010 PLoS One). These domains can mediate protein–protein interactions as well (Borden KL. et 
al.1998 Biochem Cell Biol; Nisole S. et al.2005 Nat Rev Microbiol). TRIM5α and TRIM22 contain 
only the B-box 2 (Kajaste-Rudnitski A. et al. 2010 Amino Acids). In addition, the B-box and coiled-coil 
domains of several TRIM proteins have also been described to mediate homo- and hetero- 
multimerization, promoting the formation of higher order protein complexes (Reymond A. et al. 2001 
EMBO J). Such complexes are found in different subcellular compartments, thereby determining the 
specific functions of the various TRIM proteins (Herr AM. et al. 2009 Immunogenetics). 
Several TRIM proteins also contain a C terminal SPRY domain that has been suggested to promote 
protein-protein interactions and RNA binding (Barr SD. et al. 2008 PLoS Pathog). In particular it was 
demonstrate that the SPRY domain is required for the nuclear localization of TRIM22, and its deletion 
would lead to the inability of TRIM22 to activate NF-kB (Yu S. et al. 2011 Biophys Res Commun). The 
C terminus of certain TRIM family members can also contain other different domains, such as, 
fibronectin type 3 (FN3) domains, characterized by binding sites for DNA and heparin (Ozato K. et al. 
2008 Nat Rev Immunol). The tissue distribution of TRIM proteins is extremely heterogeneous. The 
overexpression of enhanced green fluorescent protein (EGFP)-TRIM fusion proteins, have 
demonstrated that TRIM proteins are localized in specialized sub-cellular compartments both in the 
nucleus and in the cytoplasm, suggesting that individual TRIM proteins may function in a unique sub-
cellular compartments. The coiled-coil, the RING and the B-box domains are responsible for the 
specific localization of TRIM proteins; indeed mutations in these regions induce a diffuse redistribution 
of these proteins in the cell (Ozato K. et al. 2008 Nat Rev Immunol). The biological functions of TRIM 
proteins are largely unknown, but the TRIM family includes proteins with different activity such as 
tumor suppression, control of apoptosis, cell proliferation and senescence (Salomoni P. et al. 2002 
Cell).  
The numerous evidences of the effects of TRIM proteins on viral infections comes from studies of 
TRIM5α, which strongly inhibits HIV-1, acting after virus entry into cells. TRIM5α is responsible for 
the complete block of HIV-1 replication in Old World monkey cells. This effect is mediated through 
the interaction of rhesus monkey TRIM5α trimers with hexameric HIV-1 capsid proteins (Singh R. et 
al.2011 J.Virol; Stremlau M. et al. 2004 Nature). Further studies suggested that, in addition to the 
effects of TRIM5α on HIV via binding to capsid, other mechanisms of viral inhibition are possible. 
Specifically, in humans the C-terminal domain of the TRIM5α protein directly recognizes the incoming 
viral capsids (Sebastian S. et al. 2005 Retrovirology) and thereby governs antiretroviral specificity 
(Perez-Caballero D. et al.2005 J Virol; Stremlau M. et al. 2005 J Virol; Perron MJ.et al. 2006 J Virol), 
while a central coiled-coil drives TRIM5α multimerization, which is essential for inhibition. To 
antagonized TRIM5α restriction the virus exploits its capsid sequence ability to bind cyclophilin A 
(CypA), a very abundant cytoplasmic host protein. It has been suggested that CypA binding can inhibit 
restriction by TRIM5α proteins (Zhang F. et al. 2006 Virology), perhaps by coating the incoming 
capsid, or by isomerizing peptidy–prolyl bonds. In addition, TRIM5α is responsible for the species-
specific post-entry restriction of retroviruses, such as N-tropic murine leukemia virus and HIV-1, in 
primate cells (Sawyer SL. et al. 2005 Proc Natl. Acad. Sci. U S A; Singh R. et al. 2011 J Virol). Other 
TRIM E3 ligases with antiviral activity have been described (Yap MW. et al. 2004 Proc Natl. Acad. 
Sci. U S A). TRIM family proteins affect specific steps in the HIV life cycle. For most TRIM proteins, 
the exact step of the viral life cycle affected and the precise mechanisms of action are not known 
(Woods MW. et al. 2011 Retrovirology).  TRIM proteins appear to mediate their antiviral activities via 
different mechanisms: interference with the un-coating of the viral pre-integration complex was noted 
for TRIM5α, and an inhibition of viral budding has been described for TRIM22 (Ozato K. et al. 2008 
Nat Rev Immunol). TRIM22 has also been suggested to suppress HIV-1 transcription. TRIM1 has been 
shown to target the capsid protein at an early stage of infection and TRIM19 and TRIM32 have been 
demonstrated to affect trafficking of viral proteins (Nisole S. et al. 2005 Nat Rev Microbiol). TRIM28 
was shown to repress transcription by binding to proviral DNA (Wolf D. et al.2007 Cell) (Scheme 3). 








Scheme 3. Effects of human and mouse TRIM proteins on HIV-1 infection   
Stages in the life cycle of HIV, from cell binding and fusion to release from the cell are depicted on the 
left. Here are shown the human TRIM family members that are known to inhibit specific stages of the 
cycle. TRIM family members that are known to affect viral entry, viral gene expression or viral release, 
but for which the exact stage affected is not known (shown on the right). Proteins with moderate 
inhibitory or promoting effects are listed in parentheses. PML, promyelocytic leukaemia (Ozato K. et 
al. Nat Rev Immunol). 
 
 
1.2 TRIM 22  
TRIM22 was identified several years ago as Stimulated Trans-Acting Factor of 50 kDa (Staf50), an 
interferon-induced cellular gene, which represses the activity of a HIV-1 LTR- luciferase construct in 
COS-7 cells (Sawyer SL. et al.2007 Plos Pathog ; Tissot C. et al. 1995 Biol Chem). Beside IFN, 
TRIM22 is induced by viral proteins like Latent membrane protein 1 (LMP-1) which induces EBV 
latency and also by latency-associated nuclear antigen (LANA), a product of human herpesvirus 8 
(Renne R. et al.2001 J Virol ; Zhang J. et al. 2004 J Biol Chem). In human leukocytes it is expressed in 
resting T cells and down-regulated during co-stimulation with CD2 and CD28 (Gongora C. et al. 2000 
J Interferon Cytokine Res). Recently, TRIM22 has been demonstrated to be a p53 target gene and play 
an important role in cell proliferation (Obad S. et al.2004 Oncogene; Wei CL. Et al. 2006 Cell). In 
addition, TRIM22 is involved in hematopoietic differentiation and T lymphocyte activation (Duan Z .et 
al. 2008 Biochem Biophys Res Commun ). TRIM22 was one of the relatively well-characterized TRIM 
E3 ligases, which has been shown to be type 1 IFN inducible in vitro, and to possess anti-HIV-1 
activity (Meroni G. et al. 2005 Bioessays). Recent evidences suggest an in vivo antiviral activity of 
TRIM22. Indeed, it was demonstrated that the increased expression of type 1 IFNs and TRIM22 is 
associated with a significantly lower likelihood of HIV-1 acquisition and lower viral loads or higher 
CD4+ T-cell counts during primary HIV-1 infection. Remarkably, in peripheral blood mononuclear 
cells (PBMCs) from HIV-1 positive individuals TRIM22 levels strongly correlated with the expression 
of IFN-a, IFN-b, and MxA, a type 1 IFN-inducible gene, in both HIV-1-negative and -positive PBMCs 
and were up-regulated in HIV-1-positive subjects. Furthermore, TRIM22 plays a critical role in type 1 
IFN-induced anti-HIV-1 activity in tissue cultures. 
The E3 ligase activity of TRIM22 is directly correlated to its ubiquitylation capacity. In vitro and vivo 
studies have demonstrated that TRIM22 could be self-ubiquitylated in a RING finger-dependent 
manner (Duan Z .et al. 2008 Biochem Biophys Res Commun). Till now, the substrates of TRIM22 other 
than itself remain not fully understood. So far, only the Gag protein of HIV was reported to interact 
with TRIM22. However, the interaction between the Gag and TRIM22 did not affect the stability of 
Gag protein level (Barr SD. et al. 2008 PLoS Pathog).  
Recent studies in human macrophage cell line U937 have demonstrated that TRIM22 may act as a 
positive regulator of NF-kB-mediated transcription and the activation of NF-kB could significantly 
induce the secretion of pro-inflammatory cytokines. Both N terminal RING domain and C terminal 
SPRY domain were crucial for the TRIM22-mediated activation of NF-kB. In particular the deletion of 
the RING domain or the mutation of cys15 into alanine abolish TRIM22 ability to activate NF-kB. (Yu 
S. et al. 2011 Biochem Biophys Res Commun). 
 There have been conflicting reports regarding the localization of ectopically expressed TRIM22. The 
shorter form of TRIM22 (442 aa) translated from a 1329 nt coding sequence appears to localize as 
cytoplasmic aggregates with some nuclear localization. In contrast, a c-myc/flag-tagged protein product 
of the 1497 nt TRIM22 coding sequence amplified from human peripheral blood mononuclear cells 
localized exclusively in the nucleus. It should be noted that ectopically expressed TRIM22 localized 
exclusively as a nuclear protein in cells expressing low to or medium amount of protein 
(Sivaramakrishnan G. et al. 2009 Epub). 
In particular, endogenous TRIM22 forms distinct Nuclear Bodies (NB) that are regulated by signaling 
molecules including progesterone and IFN, and during the cell cycle. NB are sub-nuclear domains that 
contain an assortment of components involved in diverse nuclear functions including ribosome 
biogenesis, pre-mRNA processing, splicing, apoptosis and transport (Matera AG. et al. 1999 Trends Cell 
Biol). In ABC28 cells, endogenous TRIM22 localized as a nucleoplasmic protein and as distinct NB. 
Both nuclear forms of the protein were evidently increased by progesterone treatment. Moreover, 
TRIM22 NB are adjacent to Cajal Bodies (CB), interact with p80-coilin and undergo dynamic 
assembly and disassembly during cell cycle progression. It has been suggested that TRIM22 NB are 
dynamic structures that can form and disintegrate in response to cellular signals (Sivaramakrishnan G. 
et al. 2009 Epub). 
1.3 Class II transactivator (CIITA) 
The existence and the function of the AIR-1 locus-encoded (Accolla et al., 1986 J. Exp Med.) class II 
transactivator (CIITA), were initially identified in our laboratory by a somatic cell genetic approach 
(Accolla, 1983 J. Exp.Med.; Accolla et al., 1985 Proc. Natl. Aca. Sci; Accolla et al., 1985 J. exp. Med; 
Accolla et al., 1986, J. Exp Med). Several years later the CIITA cDNA was cloned by a 
complementation strategy (Steimle et al., 1993 Cell) by using a HLA-II negative B cell line, RJ.2.2.5, 
obtained in our laboratory by mutagenesis and immunological-selection against HLA-II DR expression 
(Accolla et al., 1983 J. Exp. Med). 
CIITA is a complex molecule of 1130 aminoacids, composed of four essential functional domains 
(Scheme 4). Its N-terminal acid region forms the transcriptional activation domain that binds 
components of general transcriptional machinery and other co-factors to direct the initiation and 
elongation of MHC-II genes transcription (Kretsovali et al., 1998 Mol Cell Biol.; Fontes et al., 1999 
Mol Cell Biol.; Kanazawa et al.; 2000 Immunity). The N-terminus of CIITA also contains the 
acetyltransferase activity (Raval et al.; 2001 Mol Cell). The proline-, serine- and threonine-rich region 
(P/S/T) is essential for the activity of CIITA (Chin et al., 1997 Proc Natl Acad Sci) and contains the 
phosphoriylation/dimerization domain (Tosi, G et al., 2002 EMBO J). The GTP-binding domain (GBD) 
and the C-terminal leucine-rich motif (LRR) are critical for the sub-cellular localization of CIITA 









Scheme 4. Functional domains of CIITA protein  
  
CIITA is a protein of 1130 amino acids with distinc functional domains indicated in the scheme. The 
red bars represent the sequences NLS (nuclear localization signal), the green bars indicate sequences 
NES (nuclear export signal); AD, activation domain, P / S / T, region rich in proline / serine / 
threonine, GBD, GTP binding domain, LRR, repeated sequences rich in leucine. 
 
 The function of CIITA can be modulated by post-translational modifications. For example, 
phosphorylation of certain residues of CIITA can increase its dimerization, its interaction with other 
key factors and its ability to trans-activate MHC class II promoters (Sisk, T. et al., 2003 Int. Immun; 
Tosi, G.et al., 2002 EMBO J). In addition, ubiquitination of CIITA increases its ability to transactivate 
MHC class II genes (Greer, S. F.et al., 2003 Nature Immunol). CIITA transcription is driven by a large 
regulatory region, which contains four distinct promoters, named pI, pII, pIII and pIV. The function of 
pII is unknown. Promoters pI, pIII and pIV precede alternative first exons that are spliced to the shared 
downstream exons, and this gives rise to three types of CIITA mRNA, which differ at their 5’ ends. pI 
promoter is used mainly by cells of myeloid origin, such as dendritic cells (DC) and by IFN-γ-activated 
macrophages; pIII is a lymphoid-cell-specific promoter essential for CIITA expression in B cells and 
activated T cells; pIV drives the expression of CIITA in thymic epithelial cells (TEC) and mediates 
induction by IFN-γ in cells of non haematopoietic origin, such as fibroblasts, astrocytes, endothelial 
and epithelial cells (Muhlethaler-Mottet, A. et al.; 1998 Immunity), (Muhlethaler-Mottet, A. et al.; 1997 
EMBO J) 
1.4 Dual role of CIITA as modulator of adaptive immunity and restriction factor 
against human retroviruses. 
MHC class II molecules are cell-surface glycoproteins that are critical to the adaptive immune system 
because they present peptides derived mainly from extracellular proteins to the antigen receptor of 
CD4+ T cells. MHC-class-II-mediated peptide presentation is essential for the positive and negative 
selection processes that shape the specificity of the T-cell-receptor repertoire of the CD4+ T-cell 
population during its development in the thymus, for the homeostasis of the mature CD4+ T-cell 
population in the periphery and for the initiation, amplification and regulation of protective immune 
responses to pathogens and tumors. To ensure tight control of these functions, MHC class II genes are 
themselves regulated in a precise cell-type-specific manner. Their expression is largely restricted to 
thymic epithelial cells (TECs) and to antigen-presenting cells (APCs), that include B cells, cells of 
monocytes-macrofage lineage and DC, specialized in the capture and presentation of extracellular 
antigens. MHC class II expression is mainly controlled at transcriptional level. All MHC-II promoters 
have conserved upstream sequences (CUS), 150–300 base pairs upstream of the transcription-initiation 
site. CUS contain few boxes present in a tightly constrained order, orientation and spacing that are 
called (from 5’ to 3’) S/W, X, X2 and Y boxes. The multiprotein complex that is assembled at the SXY 
module, which is known as the MHC class II enhanceosome, is a platform to which CIITA is recruited 
by multiple synergistic protein–protein interactions. The enhanceosome and CIITA then cooperate to 
activate transcription of MHC class II genes (De Thé G. et al. 1996 J Acquir mmune Defic Syndr Hum 
Retrovirol ; Hoffman PM. Et al. 1992 Proc Natl. Acad. Sci. USA) (Scheme 5). CIITA is a non-DNA 
binding transcriptional integrator recruited to MHC-II promoters via multiple interactions with 
transcription factors bound to DNA, including the RFX and the NF-Y complexes (Caretti G. et al. 2000 
Mol Biol; Jabrane-Ferrat N. et al. 2002 Mol Cell Biol). It interacts with CBP, p300, PCAF as well as the 
cyclin T1 subunit of the positive transcription elongation factor b (P-TEFb) to enhance MHC-II gene 
transcription (Kanazawa S. et al. 2000  Immunity ; Kretsovali A. et al 1998 Mol Cell Biol ).From one 
side, CIITA triggers the molecular events leading to transcription of MHC class II genes. In so doing, 
CIITA governs the CD4+ T cell triggering, leading to optimal activation of immune effector 
mechanisms, particularly specific antibody production by B cells. Antibody binding is a crucial event 
for neutralization of extracellular viruses, which cannot infect host cells and are driven to degradation. 
CIITA has evolved as a general defense mechanism of the host against retroviruses not only because it 
activates the adaptive immune response against the infectious agents but also because of its intrinsic 
capacity to act as an endogenous viral restriction factor (Accolla et al, 2002 Eur J Immunol, Tosi et al, 
2006 PNAS, Tosi G. et al. 2011. J Virol). For example, CIITA targets the viral transactivator Tat to 
inhibit the replication of the HIV-1 (Accolla et al, 2002 Eur J Immunol), by competing with the binding 
of P-TEFb in the elongation of HIV-1 viral transcripts (Wei P. et al. 1998 Cell).  Moreover, CIITA 
inhibits Tax-1-directed transactivation of the viral LTR and the consequent viral replication. 
Interestingly, CIITA and Tax-1 interact in vivo, and overexpression of  CREB, ATF1 and PCAF restore 
the Tax-1 mediated HTLV-1 LTR transactivation inhibited by CIITA thus suggesting the existence of 
distinct mechanism of CIITA-mediated inhibition of Tax-1 activity. (Tosi G. et al. 2011. J Virol). 
Similarly, CIITA inhibits HTLV-2 Tax transactivation and consequently HTLV-2 replication  (Casoli 
et al al 2004 Blood, Tosi et al. 2006 PNAS, Orlandi et al. 2011 J Transl Med). Preliminary studies 
suggested that CIITA could inhibit Tax-2 function via interaction with the common binding factor NF-
Y ( Tosi et al, 2006 PNAS). CIITA-NF-YB interaction in vivo is stabilized and/or favored by the 
presence of Tax-2. Thus concomitant interaction of Tax-2 with CIITA and NF-YB, most likely in the 
CIITA-NF-YB molecular complex, is at the basis of the functional inactivation of Tax-2 leading to the 
inhibition of HTLV-2 retrovirus replication. (Orlandi C. et al. 2011 J Transl Med) . 
 Taken together, these results definitely establish that CIITA, in addition to increasing the antigen-
presenting function for pathogen antigens, behaves as a viral restriction factor with an intrinsic 





Scheme 5. CIITA is a transcriptional integrator. 
 
CIITA is recruited to the promoter of MHC-II genes via multiple interactions with proteins bound to 
DNA. All promoters upstream of the MHC-II genes present in the direction 5'-3 'in the form of 
sequences highly conserved SX-X2-Y. Each of these sequences is the binding site for specific proteins. 
The heterotrimer RFX (Regulatory Factor X) binds X and S regions, the region X2 CREB/AP-1 binds 
the complex and NFY (nuclear factor Y), formed by three subunits NF-YA,-YB and-YC, binds the 
sequence Y. CIITA, once recruited to the promoter, functions as a transcriptional integrator by 
coordinating the various stages of the transcriptional process. CIITA promotes the recruitment of co-
activators that alter the accessibility of chromatin inducing histone acetylation (CBP, p300, P / CAF) or 
methylation (CARM1) and chromatin remodeling factor, BRG-1, facilitates the 'initiation of 
transcription factors binding general transcription (TFIIB and TFIID) and supports the elongation of 
transcription by recruiting the RNA polymerase II into the complex P-TEFb (Positive transcription 
elongation factor b), formed by the cyclin T1 and the cyclin-dependent kinase CDK9.   
 
 
2. Aim of the study 
 
The aim of this study was to obtain deeper insight into the cellular and molecular mechanisms 
implicated in the CIITA-mediated inhibition of retrovirus replication, particularly in the HIV system. 
As CIITA and TRIM22 share overall actions as inhibitors of HIV-1 replication  we began to investigate 
possible functional and/or molecular interactions between the two factors. 
In the first part of this study we have analyzed the anti-viral function of CIITA in a monocyte-
macrophage model of HIV-1 infection, composed of   two isogenic lines, U937 Minus and U937 Plus 
characterized by efficient or inefficient capacity to support HIV-1 replication, respectively (Franzoso 
G. et al. 1994 J. Exp. Med ). We demonstrate that the different expression in MHC class II molecules 
between the two cell lines correlates with the expression of CIITA (Minus is positive for CIITA and 
MHC class II molecules, Plus is almost negative for CIITA and for MHC class II). This correlates with 
the capacity of Minus cells to strongly inhibit Tat-mediated HIV-1 LTR transactivation  Interestingly 
the Minus and the Plus phenotype correlate also with a positive and a negative TRIM22 expression, 
respectively and  recently it was demonstrated that TRIM22 impairs HIV-1 replication by interfering 
with basal activation of viral LTR promoter (Kajaste-Rudnitski A. et al. 2001 J Virol).Thus the two 
factors have similar functions in the isogenic U937 system. To further investigate molecular correlates 
of these similarities we transfected 293T cells we demonstrate that CIITA co-immunoprecipitated with 
TRIM22, suggesting a possible cooperation between the two factors. This hypothesis was reinforced by 
localization studies of the two overexpressed proteins. When CIITA is co-expressed with TRIM22, 
most of nuclear CIITA is recruited in the specific TRIM22 nuclear bodies. 
In the second part of the study, to further detail the antiviral potential of TRIM22 and CIITA and to 
understand whether the two factors can functionally cooperate for the inhibition of HIV-1 replication in 
U937 cells, or whether their restriction activity is completely uncoupled, we decided to develop 
monoclonal antibodies against TRIM22. Whereas several specific reagents to detect and localize the 
CIITA protein are available, only a polyvalent rabbit antiserum for TRIM22 is present on the market, 
but upon direct assessment this reagent has been proved to be insufficient for serious studies of protein 
expression, intracellular localization and biochemical characterization. Moreover TRIM22 fusion 
proteins with tags such as GFP have been used but, of course, these proteins cannot be used 
satisfactorily for sophisticated studies of biochemical and biological properties of endogenously made 
proteins. 
Since our specific aim is to dissect the expression and localization of TRIM22 and to directly correlate 
its function with the function of CIITA as viral restriction factors, we decided to generate a protein 
expression system capable to provide us with sufficient amounts of TRIM22 protein and then use this 
protein to generate monoclonal antibodies against TRIM22. 
3. Materials and Methods 
 
3.1 Cell lines and animals 
 
Raji B cells and U937 promonocytic cells were maintained in RPMI-1640 (Lonza) supplemented with 
10% heat-inactivated fetal calf serum (FCS, Lonza) and 5mM L-glutamine, at 37° in a humidified 
atmosphere of 5% CO2.  
Human embryonic kidney 293T cells, HeLa Hep-2 cells were maintained in DMEM (Lonza) 
supplemented with 10% FCS and 5mM L-glutamine at 37° in a humidified atmosphere of 5% CO2.  
Murine plasmocytoma PX-63 Ag8 cells were grown in RPMI-1640 supplemented with 10% FCS,  
5mM L-glutamine and 1 X 10-4 M thioguanine. 
8-10- week-old female BALB/c mice purchased from Charles River were used for immunization. All 




Plasmids expressing myc-tagged CIITA and Flag-tagged CIITA were described in our previous study 
(Tosi, 2011). Plasmids expressing Flag-tagged TRIM22 was a gift from Prof Guido Poli. 





3.3 Transient Transfection, Luciferase Assay and Immunoprecipitation 
 
For Luciferase gene reporter assays 293T cells were seeded on 60-mm-diameter plates and transfected 
with 150ng of reporter plasmid HIV-1 LTR-Luc, 10ng of Tat expressing vector and increasing amounts 
of plasmids DNA coding for flag-tagged CIITA or flag-tagged TRIM22 (0.8µg -1.6µg), by using 
lipofectamine (Invitrogen). All the transfections were carried out in the presence of 5ng of phRL-CMV 
expressing the Renilla luciferase. Empty pcDNA3 vector was used as a stuffer DNA to maintain 
constant the total amount of transfected DNA. The lipofectamine-DNA mixture (3ul/ 1µg DNA) was 
incubated for 40 min at room temperature (RT) and then added to the cells in the presence of Opti-
MEM medium (Gibco). After 5 hours, the DNA-lipofectamine complexes were removed and complete 
DMEM medium was added to the cells. 24hrs post-transfection the cells were collected and lysed with 
Passive lysis buffer (PLB, Promega) by three cycles of freezing and thawing. Cell lysates were assayed 
for luciferase activity by using the Dual Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s instructions. Mean luciferase values, normalized to Renilla values, of at least three 
independent experiments performed in duplicate are expressed as percentages of Tat-dependent 
luciferase activity set to 100%. 
Cell lysates were analysed for the expression of CIITA and TRIM22 by SDS-PAGE on 8% 
polyacrylamide gels and western blotting with anti Flag M2 (Sigma Aldrich) and HRP-conjugated anti-
mouse IgG secondary antibody (Amersham Pharmacia). Blots were developed by chemiluminescence 
assay (ECL, Biorad).  
U937 cells were were seeded on 6-multi-well plates (2X10^6 cells/plate) and transfected with 600ng of 
reporter plasmid HIV-1 LTR-Luc, 150ng of phRL-CMV and increasing amounts of pTat (10ng -20ng) 
by using FugeneHD (Promega) at 6:1, FugeneHD: DNA ratio. Empty pcDNA3 vector was used as a 
stuffer DNA. The FugeneHD-DNA mixture was incubated for 10 min at RT and then added to the cells 
in the presence of Opti-MEM medium (Gibco). After 16 hrs, complete DMEM medium was added to 
the cells. After 24hrs the cells were collected and lysed with the PLB, as above. 
For protein binding assays, 293T cells were seeded in 100-mm-diameter plates and transfected with 
3µg of the expression vector of each interacting protein. Empty pcDNA3 vector was used as a stuffer 
DNA. 24h post-transfection cells were lysed on ice for 50 min with IP lysis buffer containing 1% NP-
40, 10mM Tris-HCl pH7.4, 150mM NaCl, 2mM EDTA, 1µM phenylmethylsulfonyl fluoride (PMSF) 
and protease inhibitors cocktail (sigma). Cell lysates were centrifuged 14.000 rpm for 10 min and the 
supernatants were pre-cleared with protein A Sepharose 4 fast flow (GE Healthcare) for 30 min at 4°C 
by rotation. An aliquot corresponding to 5% of the total cell extract was kept for proteins expression 
detection (input) 
For myc-CIITA immunoprecipitation cell extracts were incubated with anti-CIITA antibody (anti-
CIITA7-1H, Santa Cruz Biotechnology) for 1 hour on ice and then reacted with 30µl of Protein A 
sepharose 4 fast flow, overnight at 4°C by rotation. To precipitate flag-tagged TRIM22 we used the 
anti-flag M2 agarose beads (Sigma, 30µl/ sample) overnight at 4°C by rotation. The 
immunoprecipitates were washed 5 times with IP lysis buffer containing 1% NP-40, 10mM Tris-HCl 
pH7.4, 150mM NaCl, 2mM EDTA, 0.1% protease inhibitors, and 1 time with the same lysis buffer 
containing 500mM NaCl. Co-immunoprecipated proteins were analysed by western blots with the anti-
CIITA monoclonal antibody, or the anti-Flag M2 monoclonal antibody and HRP-conjugated anti-
mouse secondary antibodies.  
Endogenous CIITA was precipitated from U937 cells and Raji B cells (30X10^6 or 15X10^6 cells, 
respectively). After pre-clearing, the cleared lysates were incubated with 1µg of anti-CIITA antibody 
(anti-CIITA7-1H, Santa Cruz Biotechnology) 1 hour on ice and then reacted with 50µl of Protein A 
beads overnight at 4°C by rotation. The immunoprecipated proteins were analysed by western blots 
using anti-CIITA monoclonal antibody.  
3.4 SDS/PAGE and Western blotting 
 
U937 cells (8X10^6) were collected and lysed with lysis buffer containing 1% NP-40, 10mM Tris-Hcl 
pH 7.4, 150mM Nacl, 2mM EDTA, 1µM PMSF and protease inhibitors cocktail. Cell debris were 
removed by centrifugation at 14.000 rpm for 10 min at 4°C and the supernatants were collected. Cells 
lysates were analysed for the expression of TRIM22 proteins in denaturing and in not-denaturing gel 
electrophoresis, followed by western blotting. For the denaturing gel electrophoresis the lysates were 
diluted with 6x SDS-sample buffer (0.3M Tris-HCL pH6.8, 0.6 M DTT, 10% SDS, 0.6% bromophenol 
blue, 60% glycerol) and boiled for 3 min before loading on the gel. For the not-denaturing gel 
electrophoresis, the lysates were diluted with 6x SDS-sample buffer lacking SDS, without boiling. 
Proteins were then separated by electrophoresis on 8%-polyacrylamide gel containing 0.1% SDS, and 
then transferred into a nitrocellulose membrane (Hybond-C, GE Healthcare) by electroblotting 
(360mA, for 1hour) at 4°C. After blocking with 5% non-fat dry milk in PBS for 1 hour at RT, the 
membrane was incubated with the primary antibodies (Supernatants of hybridoma cell lines, see below) 
diluted 1 to 2 with 5% non-fat dry milk in PBS, overnight at 4°C under agitation. The membrane was 
then washed three times for 10 min with PBS then incubated with the secondary antibody solution 
(HRP-conjugated goat anti-mouse secondary antibodies) for 2 hrs at RT, under agitation. After five 
washes (10min each) with PBS and one wash with PBS containing 0,05% Tween 20, blots were 
developed by ECL. 
3.5 FACS analysis 
U937 Plus and Minus cells (1X10^5) were collected and washed with PBS. Cells were then incubated 
with the anti HLA-II DR (D1.12) monoclonal antibody, for 30 min at 4°C. After washing, cells were 
incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG secondary antibody for 
30 min at 4°C. As a control, cells were incubated only with the secondary antibody. Expression of 
HLA molecules was analysed by flow cytometer (EPICS XL flow cytometer) and EXPO32 analysis 
software (Beckman Coulter S.p.A., Milan, Italy). 
 
3.6 Real time RT-PCR  
 
Total RNA was extracted using TRIzol reagent (Life Technologies). cDNA was synthesized from 2 µl 
total RNA using oligo(dT) primers and M-MLV reverse transcriptase (Promega). Quantitative real-time 
PCR (QRT-PCR) was performed using IQSYBR Green PCR reagent on an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems) according to the manufacture's protocol. The HLA-II DR, 
CIITA, TRIM22 and RPS7 (Ribosomal protein S7, used as control to normalize for cDNA quantity) 
transcripts were amplified using specific primers (Table 1). Changes in fluorescence of the SYBR 
Green I dye in each cycle were monitored, and the cycle threshold (Ct), which is defined as the cycle 
number at which the amount of amplified target reaches a fixed threshold, was obtained for each gene. 
The relative amount of PCR products, generated from each primer set was determined on the basis of 
the Ct value. The expression difference for each gene  (gene x) between control and samples was 
calculated by normalizing Ct values with RPS7 gene expression according to the formula: 
Relative mRNA expression = 2[[Ct (control) gene x - Ct (sample) gene x] - [Ct (control) RPS7 – Ct 
(sample) RPS7. 
Table 1 – Forward and reverse primers used in QRT-PCR 
 
Gene  Forward primer (5’-3’) 
  











hRPS7   TGGAGATGAACTCGGACCTC  CGACCACCACCAACTTCAA 
 
 
3.7 Immunofluorescence analysis 
 
Hep-2 cells were transfected with plasmids expressing myc-tagged CIITA (0.5µg) and flag-tagged 
TRIM22 (0.5µg). At 24 hrs post-transfection, cells on coverslips were fixed in methanol for 6 min at -
20°C and blocked with 0.5% BSA in PBS for 1 hour at RT. Cells were then incubated with anti-myc 
polyclonal antibody (anti-mycA14, 1:200 dilution 0.1% BSA in PBS, Santa Cruz Biotechnology) and 
with anti-FITC conjugated Flag monoclonal antibody (1:200 dilution 0.1% BSA in PBS, Sigma) 
overnight at 4 °C in the dark, followed incubation with Alexa-Fluor 546 goat anti rabbit secondary 
antibody (1:500 dilution in 0.1% BSA in PBS,  Life technology) for 1 hr at RT, in the dark. Cells were 
then examined under a confocal laser-scanning microscope, Leica TCS SP5 (objective lenses: HCX PL 
APO, 63X original magnification, numerical aperture: 1.25) and imported into LAS AF software.  
 
3.8 Immunization and monoclonal antibody production 
 
TRIM22-intein recombinant protein was used as antigen for the generation of TRIM22 monoclonal 
antibodies and was injected (about 5µg) intraperitoneally into BALB/c mice tree times, specifically at 
day 1, 14 and 28. The first immunization was performed in presence of Complete Freund’s Adjuvant 
(CFA), whereas the second and third immunizations were performed in presence of Incomplete 
Freund’s Adjuvant (ICFA). Tree to five days after the last immunization, the immunized animals were 
killed and the splenocytes used for fusion. Hybrid cell lines were obtained by fusing antibody-
producing B cells with HGPRTneg  myeloma cells. The fusion was accomplished using polyethylene 
glycol (PEG). Fused cells were cultured in four 24-multi-well plates on monolayer of peritoneal 
macrophages of mice BALB/c in presence of HAT (Hypoxantin Aminopterin Thymidine) medium. 
Aminopterin blocks the pathway that allows for nucleotide synthesis. Hence, unfused myeloma cells 
die, as they cannot produce nucleotides by the de novo or salvage pathways because they lack HGPRT. 
Removal of the un-fused myeloma cells is necessary because they have the potential to outgrow other 
cells. Unfused B cells die as they have a short life span. In this way, only the B cell-myeloma hybrids 
survive, since the HGPRT gene coming from the B cells is functional. After about 14 days, hybridoma 
culture supernatants were collected and we identified and selected only those hybridomas that produce 




4.1 CIITA is expressed only in U937 Minus cells 
Previous results demonstrated that the MHC-II transactivator CIITA inhibits HIV-1 replication in 
human T cells by competing with the viral transactivator Tat for the binding to the Cyclin T1 subunit of 
the PTEF-b transcriptional elongating complex (Accolla R. S. et al. 2002 Eur. J. Immunol). 
In order to assess whether the anti-viral function of CIITA is present in mononuclear phagocytes, which 
represent another important target of HIV-1 infection, we studied two phenotypically and functionally 
distinct isogenic cell clones of U937characterized by efficient or inefficient capacity to support HIV-1 
replication, named Plus and Minus, respectively (Franzoso G. et al. 1994, J Exp Med). 
First, we analyzed the cell surface expression of MHC-II molecules in U937 Plus and Minus clones by 
FACS analysis. Interestingly, only U937 Minus cells express HLA-II DR whereas U937 Plus cells do 
not (Fig.1A). This correlates with HLA-II DR mRNA expression in U937 Minus cells and in U937 Plus 
cells, as assessed by QRT-PCR. Raji B cells were used as a positive control for HLA-II DR mRNA 
expression (Fig.1B).  
To verify whether this different phenotype correlates with the expression of functional CIITA protein 
restricted to Minus clones, CIITA mRNA expression in both U937 Minus and Plus cells was assessed 
by real-time PCR. U937 Minus cells clearly express CIITA mRNA, whereas Plus cells do not (Fig.2A).  
Raji B cells were used as a positive control for CIITA mRNA expression.  We further assessed whether 
the observed differences in CIITA mRNA expression correlated with the protein expression. 
Immunoprecipitation following immunoblotting (IP: αCIITA, WB: αCIITA) with an anti-CIITA 
antibody detected CIITA only in Minus cells, confirming the expression of CIITA only in these cells 
(IP: αCIITA, WB: αCIITA Fig. 2B).   
In conclusion, the phenotype of U937 Minus and Plus clones shows the additional correlation of 
expressing or not expressing MHC class II molecules as a function of expression or non expression of 
CIITA, respectively. 
 
4.2 Both CIITA and TRIM22 inhibit Tat-dependent HIV-1 LTR transactivation  
Previous data demonstrate that CIITA inhibit HIV-1 transcription, by blocking Tat activity in Jurkat T 
cells (Accolla RS. et al.2002 Eur J Immunol). In addition, it has been reported that TRIM22 inhibits 
basal HIV-1 transcription in U937 cells without affecting HIV-1 Tat transactivation (Kajaste-Rudnitski 
A. et al. 2011 J. Virol). Interestingly, TRIM22 is specifically expressed in U937 Minus cells but not in 
Plus cells as reported by Kajaste-Rudnitski A. et al. (J. Virol 2011), and further confirmed in by our 
studies (Fig.2C).  
To investigate the possible relationship between CIITA and TRIM22 in the inhibition HIV-1 
transcription, we first examined the effect of expression of the two factors on the transcriptional activity 
of HIV-1 Tat, by reporter gene assay. We co-transfected human 293T cells with the HIV-1 LTR 
luciferase reporter construct and the expression vector for Tat, alone or together with increasing 
amounts of a plasmid coding for Flag-tagged CIITA, or for Flag-tagged TRIM22 (0.8µg – 1.6µg). We 
found that the overexpression of CIITA or, surprisingly, TRIM22 could inhibit Tat activity in dose-
dependent manner, (Fig.3A, B).  
The observed inhibition of Tat transactivation by CIITA and TRIM22, prompted us to investigate 
whether this suppressive effect was confirmed also in the isogenic U937 cell system. To this aim U937 
Minus and Plus cells were co-transfected with fixed amounts of the reporter construct HTLV-1 LTR-
luciferase and increasing amounts of Tat expression vector (10ng - 20ng). Interestingly, we found that 
Tat-dependent LTR transactivation is strongly reduced in Minus cells with respect to Plus (Fig.3C), 
indicating a possible cooperation between CIITA and TRIM22 in the inhibition of Tat-mediated HIV-1 
transcription. 
 
4.3 CIITA interacts with TRIM22 in vivo 
To further investigate the molecular and functional relationship between CIITA and TRIM22 we 
assessed whether the two proteins physically interact each other. To test this hypothesis, myc-tagged 
CIITA and Flag-tagged TRIM22 were co-expressed in 293T cells. Cell lysates were 
immunoprecipitated with anti-flag antibody and TRIM22-bound proteins were assessed for the 
presence of CIITA by Western blotting. As shown in Figure 4, CIITA co-precipitated with TRIM22 
(IP: α flag, WB: α CIITA, lane 4). The interaction between the two factors was not so evident when the 
immunoprecipitation step was first performed with anti-CIITA antibodies, instead of anti-FlagTRIM22 
antibody (Fig.4, IP: α CIITA WB: α flag, lane 4), possibly suggesting that the epitope recognized by 
anti-CIITA antibody spatially overlaps the site of interaction between CIITA and TRIM22. 
 
4.4 Nuclear CIITA is mainly recruited into TRIM22 nuclear bodies 
To assess where CIITA-TRIM22 physically interact at the sub-cellular level, we performed the 
confocal microscopy analysis on Hep-2 cells transiently transfected with myc-tagged CIITA and flag-
tagged TRIM22. As we expected, CIITA is homogeneously diffused in the nucleus and in the 
cytoplasm of Hep-2 cells (Fig. 5A, panel a), whereas TRIM22 localizes as a nucleoplasmic protein in a 
spot-like distribution reminiscent of nuclear body structures (Fig.5A, panel b). Interestingly, in the 
presence of TRIM22, nuclear CIITA is mainly recruited into TRIM22 nuclear bodies, further 
suggesting a functional relationship between the two factors (Fig.5 B, panel a’’, overlay).  
Future work in this area should include an investigation into the association between TRIM22's nuclear 
localization, CIITA recruitment into TRIM22 nuclear bodies and their antiviral properties in U937 
Minus cells.  
Unfortunately, no specific reagents, such as monoclonal antibodies, are available for the detection and 
the localization of endogenous TRIM22 protein. Thus we decide to generate mouse monoclonal 
antibodies against recombinant TRIM22 protein. 
 
4.5 TRIM22 Cloning  
The first step for the generation of monoclonal antibodies was to produce sufficient amount of antigen 
to immunize mice. This was accomplished by the following strategy. TRIM22 c-DNA was cloned into 
an E.coli expression vectors with specific expression tags or fusion proteins to express them in a basic 
E.coli strain. The second step was the purification of the protein used as antigen for the production of 
the monoclonal antibodies in mice.  
First, the TRIM22 coding sequence was amplified by polymerase chain reaction (PCR) from TRIM22-
pcDNA3.1, using the following primers: 
The forward (FW) 5’-GGCCCATATGACCATGGATTTCTCAGTA-3’, which introduced an NdeI 
restriction site (blue) into the N-terminus of TRIM22 coding sequence (red) and the reverse (RW) 5’- 
CCCACCGAGCTCCCTCGAGTATCTA-3’, which introduced an XhoI restriction site (blue), 
immediately before the first TGA stop codon of TRIM22 sequence  (red). Each primer contains extra 
bases (black) near the restriction site, in order to allow a complete digestion by the corresponding 
enzyme. The amplified sequence was sub-cloned into a pGEMT easy vector (Promega) and easily 
digested using NdeI and XhoI restriction enzymes.  
The digested fragments containing the TRIM22 gene were cloned into pTYB1 (NEB) in frame with the 
Intein gene, to generate TRIM22-Intein fusion protein expression in E.coli (Fig.6, pTYB1-TRIM22). 
The inserted cDNA and the flanking regions were sequenced to control the integrity of the sequence.  
 
4.6 Expression and purification of TRIM22-intein recombinant protein 
The great advantage of pTYB vectors is the possibility to obtain a TRIM22-untagged protein. This 
system utilizes the inducible self-cleavage activity of the Intein, to separate the target protein from the 
tag. The Intein contains also a chitin-binding domain necessary for the purification of the fusion protein 
on chitin beads. After beads purification, 1,4-Dithiothreitol (DTT) induces cleavage, resulting in the 
elution of the untagged TRIM22. 
A protein expression competent E.coli strain (ER2566) was transformed with pTYB1-TRIM22 vectors. 
Four colonies from the overnight LB-Agar plate culture were picked to select one for the best 
expression. Colonies were amplified in 200ml of LB media of at 37°C, overnight under agitation to 
reach the desired concentration (OD600nm=0.6) TRIM22-intein protein expression was then induced by 
adding 0.5 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and culturing for 3.5 hrs at 30 °C. 
Bacteria were finally centrifuged and corresponding pellet was lysed. We tried different lysis buffers 
and lysis conditions, as the TRIM22-intein recombinant protein was found to be rather insoluble. The  
final selected procedure was the following. Bacterial pellet was collected by centrifugation at 4500 
rpm, at 4°C for 15 min, re-suspended in Lysis Buffer (1 ml) containing urea 8M in PBS and protease 
inhibitors, lysed by sonication and then solubilized overnight at 4°C, by rocking. After centrifugation at 
14000 rpm, at 4°C for 15 min, both the soluble fraction (SN) and the pellet fraction (PT) were analyzed 
by SDS-PAGE and Comassie blue staining. As shown in figure 7, a band corresponding to TRIM-
Intein recombinant protein (100 KDa) was detected on IPTG-induced bacterial cultures (Fig.7, compare 
lane 3 to lane 2). We were able to solubilize at least 50% of the protein using 8M urea lysis buffer (fig. 
7, compare lane 8 to lane 4).  
The TRIM22-intein recombinant protein was purified using chitin beads (NEB). Washed beads (40 ul) 
were added to the soluble protein extracts (SN) and incubated at 4°C for 3 hrs. After washes, the Intein-
self cleavage was induced by adding 40 mM DTT (200 ul) to the beads and furher incubation at 4°C for 
2 hrs in the dark. The eluted proteins were detected by SDS-PAGE, and Comassie blue staining. 
Unfortunately, we were not able to obtain purified TRIM22 protein, possibly for the partial 
denaturation of the intein protein, during the urea treatment (Fig.7, lane 5). Thus, we decide to use 
TRIM22-intein fusion protein as antigen for the production of monoclonal antibodies in mice.  
 
4.7 Generation, screening and characterization of TRIM22 monoclonal antibodies 
In order to generate monoclonal antibodies (mAb) specific for TRIM22, BALB/c mice were injected 
intraperitoneally three times with 3µg TRIM22-intein every two weeks; first injection was carried out 
in CFA followed by the second injection in ICFA, and by the third in PBS. Spleen cells from 
immunized mice were used to prepare somatic cell hybrids with the plasmocytoma PX-63 Ag8. mAb 
containing supernatants were checked for anti-TRIM22 specificity by western blots in denaturing and 
non-denaturing condition, using protein extracts obtained form U937 Plus and Minus cells.  
Cumulative results of the screening are summarized in the Table1. Figure 8 shows some of the most 
representative results of the screening. Similar results were obtained in denaturing and not-denaturing 
gels. Interestingly, the hybridoma supernatant L91 detects a band at 55 kDa only in U937 Minus cells, 
probably corresponding to TRIM22  (Fig.8A, lane 3). We also found another hybridoma supernatant, 
the L92, with the same specificity (not shown in the figure). Interestingly, the hybridoma supernatant 
L85 detects a band of 100 kDa only in U937 Minus cells, which may be related to an ubiquitinated 
form of TRIM22 (Duan Z .et al. 2008 Biochem Biophys Res Commun) (Fig.8 lane 3).  Figure 8 also 
shows two negative results related to the mAb L40, which could not detect any band (Fig.8A, lane 1), 
and the mAb L95, which detects a band at 72 kDa in both Plus and Minus cells (Fig. 8A, lane 2). 
To further characterized the L91 and L92 mAbs, which detect a band at 55 kDa in Minus cells possibly 
corresponding to TRIM22, we looked for the antibody subtype by western blot using HRP-conjugated 
goat anti-mouse IgG or goat anti mouse IgM secondary antibodies. The anti-HLA-I antibody B9.12.1 
(IgG subtype) was used as control. 
As shown in figure 8 B, the goat anti-mouse IgG could detect the light and heavy chains (50 kDa and 
25 kDa) of B9.12.1 antibody, whereas the goat anti mouse IgM antibody could only detect the light and 
heavy chains (50 kDa and 25 kDa) of L91and L92 antibodies. This result clearly indicates that the two 
monoclonal antibodies L91 and L92 against TRIM22 are of  IgM subclass. 
Further experiments are planned to definitively assess the specifity of these antibodies for TRIM22. 
5. Discussion 
Characterization of host factors restricting HIV-1 infection may provide important information on the 
mechanisms used by the virus to efficiently infect and replicate in different target cells. Recent studies 
have demonstrated that the restriction factor TRIM22 inhibited HIV-1 LTR-driven transcription and 
virus replication in a model represented by isogenic U937 promonocitic cell lines characterized by 
efficient (Plus) or inefficient (Minus), capacity to support productive HIV-1 replication respectively 
(Kajaste-Rudnitski A. et al. 2011 J Virol)  
In this work we have investigated the inhibitory effect of the MHC-II transactivator CIITA on HIV-1 
transcription in U937 Plus and Minus promonocytic cell lines. In addition to TRIM22, also CIITA was 
differentially expressed in U937 Plus and Minus cells, with Plus cells lacking detectable mRNA and 
protein expression. Thus, the phenotypic analysis of these cells shows that, in contrast to Minus cells, 
Plus cells do not express HLA-II molecules because of a defect in MHC-II gene transcription due to 
the absence of the MHC-II transactivator CIITA. In searching for the molecular mechanisms at the 
basis of CIITA and TRIM22-mediated inhibition of HIV-1 transcription, we demonstrated that CIITA 
and TRIM22 inhibit HIV-1 replication by targeting the LTR-dependent transcriptional activating 
function of the viral transactivator Tat, in 293T cells transfected with increasing amounts of CIITA or 
TRIM22 expressing plasmid. In contrast to our results, Kajaste-Rudnitski A. et al. observed that 
TRIM22 did not interfere with Tat-mediated HIV-1 replication when overexpressed in 293T cells. To 
date, we cannot explain these different data but since this inhibitory effect was observed when Tat was 
transfected into U937 Minus cells expressing endogenous CIITA and TRIM22, we conclude that 
physiologic amounts of the two proteins might contribute to the “nonpermissive” phenotype of U937 
Minus cells for HIV-1 infection. At present, the relative contribution of CIITA or TRIM22 to the 
inhibition of viral replication in Minus cells cannot be precisely assessed. Within this frame, it will be 
important to investigate the Tat activity in U937 Minus cells in which CIITA or TRIM22 were 
silenced. That CIITA and TRIM22 may cooperatively act for the resistant phenotype to HIV-1 
replication observed in Minus cells is also strongly suggested by our additional findings on the physical 
interaction and subcellular colocalization of the two restriction factors. Indeed we found, for the first 
time, that CIITA, a restriction factor also for HTLV infection (Tosi, 2011, Orlandi 2011), interacts in 
vivo with TRIM22. We also analyzed the sub-cellular localization of CIITA and TRIM22 and we 
observed that the nuclear CIITA in mainly recruited into TRIM22 nuclear bodies, in Hep-2 cells over-
expressing the two proteins. Interestingly, TRIM22 nuclear bodies are also frequently observed next to 
and within nucleoli. It is likely therefore that TRIM22 is involved in one or more nucleolar functions, 
which include rDNA transcription, pre-rRNA processing, ribosome assembly and formation of the 
telomerase ribonuclear protein complex, and more importantly the nucleolus has been suggested as a 
gateway for viral replication (Sivaramakrishnan G et al. 2009 Exp Cell Research). Viral proteins are 
known to interact with nucleolar proteins such as B23 and fibrillarin and use the nucleolus as a site of 
replication. In addition Tat was reported to be present primarily in the nucleolus of transfected and 
infected cells (Cullen et al., 1988, Luznik et al., 1995, Stauber and Pavlakis 1998). In contrast, CIITA 
has never been found in the nucleoli. The findings of CIITA recruitment into TRIM22 nuclear bodies 
certainly warrants future work to possible correlate the association between TRIM22's nucleolar 
localization, CIITA and their antiviral properties.  
As a preliminary step to further refine the subcellular localization and the intimate function of 
endogenous TRIM22, we are exploring the possibility to produce monoclonal reagent against TRIM22. 
Out of two somatic cell fusions we have obtained a series of mAbs that are presently under accurate 
scrutiny. The antibodies L91 and L92 which detected a band at around 50–60 kDa in U937 Minus cells 
are good candidates for being TRIM22-specific. Additionally, the monoclonal antibody L85 detected a 
band at around 100 kDa. We have hypnotizes that L85 mAb should react against an ubiquitinated form 
of TRIM22 (Duan Z. et al. 2008 Biochem and Biophysical Res). To confirm our hypothesis it will be 
necessary to sequence the bands recognized by the two antibodies by using Mass-spectrometry 
analysis.  
In conclusion these results confirm the important role of CIITA and TRIM22 in the pathogenesis of 
HIV-1 infection and indicate that different host factors may contribute to inhibit HIV-1 expression in 
monocytes-macrophages target cells. We believe that CIITA acts as a new versatile antiviral factor, 
which may be useful to develop innovative preventive and therapeutic approaches to counteract HIV-1 





6.Figures   
 
 
Fig.1  U937 Minus cells expresses MHC-II molecules 
(A) The cell surface expression of MHC-II molecules was assessed by FACS analysis in U937 Plus 
and Minus clones. Only U937 Minus cells express HLA-II DR (white histogram in upper panel) 
whereas U937 Plus cells do not. Gray histogram represent negative control. (B) HLA-II DR mRNA 
expression in U937 Minus cells and in U937 Plus cells was assessed by QRT-PCR. HLA-II DR mRNA 
expression in Minus cells was normalized to 1. All mRNA levels are relative to RPS7 mRNA 
expression.  Raji B cells were used as a positive control for HLA-II DR mRNA expression  
 
Fig.2  U937 Minus cells constitutively express endogenous CIITA  
(A) CIITA mRNA expression in both U937 Minus and Plus clones, was assessed by real-time PCR. 
U937 Minus cells clearly express CIITA mRNA, whereas Plus cells do not. Raji B cells were 
used as a positive control for CIITA mRNA expression. (B) Total cell lysates were 
immunoprecipitated with an anti-CIITA antibody and then analyzed for the expression of 
CIITA by Western Blotting (IP: αCIITA, WB: αCIITA). CIITA protein is exclusively 
expressed in U937 Minus cells. (C) TRIM22 mRNA levels were analyzed by QRT-PCR. 





Fig.3 CIITA and TRIM22 inhibt Tat-mediated HIV-1 LTR transactivation in a 
cotransfection system and in U937 Minus cells. 
293T cells were co-transfected with fixed amounts of pHIV-1 LTR-Luc, phRL-CMV, pTat (10 ng) and 
with increasing amounts (0.8-1.6µg) of plasmid coding for flag-tagged CIITA (A) or flag-tagged 
TRIM22 (B) (hatched columns 3-4). Mean luciferase activities, normalized to Renilla activity, are 
presented in the ordinate as percentages relative to activation by Tat set to 100% (black, column 2). 
Column 1 represents the activity of pcDNA3 vector in the absence of Tat. Expression of recombinant 
flag-CIITA (fCIITA) and flag-TRIM22 (fTRIM22) proteins was assessed in cell extracts by Western 
blotting with anti-flag antibody. (C) U937 Plus (gray columns) and Minus (black columns) cells were 
co-transfected pHIV-1 LTR-Luc, phRL-CMV, and increasing amounts of a Tat expression vector (10, 
20 ng). Mean luciferase activities, normalized to Renilla activity are presented in the ordinate as fold of 






Fig.4  CIITA and TRIM22 interact in vivo 
293T cells were transfected with myc-CIITA (mCIITA) and flag-TRIM22  (fTRIM22) expression 
vectors in different combinations, as indicated. pCDNA3 was used as stuffer DNA (mock). Anti-flag 
agarose beads  (IP:a flag) or anti-CIITA (IP:a CIITA) precipitated proteins were analyzed for the 
presence of TRIM22 and CIITA by immunoblotting with anti-CIITA (WB:a CIITA) or with anti-flag 






Fig.5 CIITA and TRIM22 co-localizes in vivo 
 Expression of TRIM22 proteins leads to the recruitment of nuclear CIITA in TRIM22 nuclear bodies. 
(A) Hep2 cells were transfected with the myc-CIITA (mCIITA) or flag-TRIM22 (fTRIM22) expression 
vectors. The cells were fixed and stained with anti-myc rabbit polyclonal antibody for the detection of 
CIITA proteins (A, a) or with FITC-conjugated anti-FLAG monoclonal antibody for the detection of 
TRIM22 proteins (A, b). (B) Hep2 cells were co-transfected with the vectors expressing mCIITA and 
fTRIM22. The cells were fixed and stained by double immunofuorescence staining with anti-CIITA 
rabbit polyclonal antibody (B, a) and FITC-conjugated  anti-FLAG monoclonal antibody directed 
against the flag epitope to detect TRIM22 proteins (B, a’). The the overlay images are depicted in a’’. 
Differential interference contrast (DIC) images are also shown.  
PCR amplification
















Fig.6 TRIM22 Cloning 
TRIM22 coding sequence was amplified by polymerase chain reaction (PCR) from pcDNA3.1- 
TRIM22. usng  primer partly homologous to the consensus TRIM22 sequence. The amplified sequence 
was sub-cloned into a pGEMT easy vector and was digested using NdeI and XhoI restriction enzymes. 








   
  
 
Fig.7 Expression and purification of TRIM22-intein recombinant protein 
Lysates from bacteria transformed with TRIM22-intein plasmid construct. Samples were analyzed by 
SDS-PAGE and Comassie blue staining. Protein molecular weight marker (MW lane 1);  the total 
lysate containg all bacterial proteins before induction by IPTG (NI, lane 2), and  after IPTG induction 
(IND, lane 3). The Urea supernatants (SN, lane 7) and the corresponding protein pellet (PT, lane 8) 
were analysed. TRIM22-intein eluted protein (EL) was shown in lane 5. Lanes 6 and 7 are fixed 




Fig.8 Generation, screening and characterization of TRIM22 monoclonal 
antibodies. 
(A) Western blot of the selected TRIM22 hybridoma supernatants (L40, L95, L85, L91) on U937 Plus 
and Minus cell lysates. (B) The sub-class of L91 and L92 monoclonal antibodies use in different 
combination (as indicated) was identified by western blot.  The HRP-conjugated goat anti-mouse IgG 
or goat anti mouse IgM secondary antibodies were used. The anti-HLA-I antibody B9.12.1 (IgG 
subtype) was used as control.  
 
 
   Hybridoma            U937  Cells      Hybridoma              U937   Cells 
Supernatants      Plus      Minus   Supernatants      Plus      Minus 
L1      ND    ND   L49      ND    ND 
L2      ND    ND   L50      ND    ND 
L3      ND    ND   L51     Bands     Bands 
L4      ND    ND   L52      ND      ND 
L5      ND    ND   L53      ND      ND 
L6      28 KDA      28 KDA   L54      ND      ND 
L7      ND    ND   L55    200KDA    200KDA 
L8      ND    ND   L56      ND      ND 
L9      ND    ND   L57      ND      ND 
L10      ND    ND   L58      ND      ND 
L11      ND    ND   L59     72KDA     72KDA 
L12      ND    ND   L60      ND      ND 
L13      ND    ND   L61      ND      ND 
L14      ND    ND   L62      ND      ND 
L15      ND    ND   L63      ND      ND 
L16      72 KDA      72 KDA   L64      ND      ND 
L17      28KDA      28KDA   L65      ND      ND 
L18     Bands     Bands   L66      ND      ND 
L19      28KDA      28KDA   L67     46KDA     46KDA 
L20      28KDA      28KDA   L68     50KDA     50KDA 
L21     Bands     Bands   L69      ND      ND 
L22     Bands     Bands   L70      ND      ND 
L23      28KDA      28KDA   L71      250KDA      250KDA 
L24      28KDA      28KDA   L72      ND      ND 
L25      ND    ND   L73      36KDA      36KDA 
L26      ND    ND   L74      ND      ND 
L27      ND    ND   L75      ND      ND 
L28      ND    ND   L76      ND      ND 
L29      ND    ND   L77      ND      ND 
L30      ND    ND   L78      ND      ND 
L31      ND    ND   L79      ND      ND 
L32      ND    ND   L80      ND      ND 
L33      ND    ND   L81      ND      ND 
L34      45KDA      45KDA   L82      ND     100KDA 
L35      ND      ND   L83      ND      ND 
L36      ND      ND   L84     72KDA     72KDA 
L37      ND      ND   L85      ND     100KDA 
L38      50KDA      50KDA   L86      ND      ND 
L39      ND      ND   L87     Bands     Bands 
L40      ND      ND   L88      ND      ND 
L41      ND      ND   L89     46KDA     46KDA 
L42      ND      ND   L90      ND      ND 
L43      ND      ND   L91     Bands     55KDA 
L44      250KDA      250KDA   L92     Bands     55KDA 
L45      ND    ND   L93     72KDA     72KDA 
L46      ND    ND   L94     72KDA     72KDA 
L47      ND    ND   L95     72KDA     72KDA 
L48      ND    ND   L96      ND      ND 
 
 
Table1: Summary of the analysis of the hybridoma supernatants 
Hybridoma supernatants (column 1) were analysed by western blot using U937 Plus and Minus cell 
lysates (column 2). In this table were indicated molecular weights of specific bands detected; ND:  Not 
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